{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:38:22Z","timestamp":1776494302812,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10384-025-01287-z","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:58:42Z","timestamp":1760500722000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcomes of patients with neovascular age-related macular degeneration after switching from aflibercept to faricimab"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-977X","authenticated-orcid":false,"given":"Yuji","family":"Oshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Himeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michika","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM200002173420707","volume":"342","author":"SL Fine","year":"2000","unstructured":"Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483\u201392.","journal-title":"N Engl J Med"},{"key":"1287_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"1287_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S-J, Chen Y, Guymer R, et al. TENAYA and LUCERNE two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326.","journal-title":"Ophthalmology"},{"key":"1287_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1287_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"1287_CR7","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"1287_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2147\/OPTH.S501953","volume":"19","author":"I Wada","year":"2025","unstructured":"Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, et al. Five-year outcome of aflibercept administration with treat and extend for neovascular age-related macular degeneration. Clin Ophthalmol. 2025;19:835\u201345.","journal-title":"Clin Ophthalmol"},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from altair: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. The angiopoietin\/tie pathway in retinal vascular diseases: a review. Retina. 2021;41:1\u201319.","journal-title":"Retina"},{"key":"1287_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcp.10442","volume":"199","author":"Y Oshima","year":"2004","unstructured":"Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004;199:412\u20137.","journal-title":"J Cell Physiol"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/OPTH.S395279","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041\u20136.","journal-title":"Clin Ophthalmol"},{"key":"1287_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","volume":"67","author":"T Hikichi","year":"2023","unstructured":"Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"1287_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023;12:5145.","journal-title":"J Clin Med"},{"key":"1287_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00629-w","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, Forte P, Forte G, Eandi CM. Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Na\u00efve and switch eyes. Int J Retina Vitreous. 2025;11:3.","journal-title":"Int J Retina Vitreous"},{"key":"1287_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41433-024-03583-3","volume":"39","author":"A Nadel","year":"2025","unstructured":"Nadel A, Drakopoulos M, Bains HK, Bar-Meir A, Marchese A, Lyon AT, et al. Analysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD. Eye. 2025;39:1337\u201343.","journal-title":"Eye"},{"key":"1287_CR19","volume":"16","author":"D Sutter","year":"2024","unstructured":"Sutter D, Anderson A, Wheatley S, Sheth V. Quantifying fluid and function in suboptimal responders switched from an anti-vascular endothelial growth factor (VEGF) to faricimab. Cureus. 2024;16:e56652.","journal-title":"Cureus"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00417-019-04361-8","volume":"257","author":"I Wada","year":"2019","unstructured":"Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch Clin Exp Ophthalmol. 2019;257:1411\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1287_CR21","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Leithner PL, Foxton R, Barathi VA, Cheung CMG, Tun SBB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265\u201388.","journal-title":"EMBO Mol Med"},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00417-021-05445-0","volume":"260","author":"S Inoda","year":"2022","unstructured":"Inoda S, Takahashi H, Inoue Y, Tan X, Tampo H, Arai Y, et al. Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid\/drusen perspective. Graefes Arch Clin Exp Ophthalmol. 2022;260:747\u201358.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1287_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/life14040476","volume":"14","author":"A Machida","year":"2024","unstructured":"Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E, et al. Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept. Life. 2024;14:476.","journal-title":"Life"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01287-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01287-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01287-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:39:54Z","timestamp":1776490794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01287-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01287-z","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Oshima, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Chugai, Senju, Bayer, Otsuka, Novartis); N. Himeno, None; T. Nakamura, None; Y. Ando, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis); N. Takaki, None; M. Hirata, None; A. Yamamoto, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Chugai, Senju, Bayer, Novartis).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}